세계의 원내 감염 치료(HAI) 시장 : 기회와 촉진요인, 업계 동향 분석 및 예측(2024-2032년)

The Global Hospital Acquired Infections Therapeutics Market was valued at USD 12.6 billion in 2023 and is expected to grow at a CAGR of 3.2% from 2024 to 2032. This growth is largely driven by the rising incidence of healthcare-associated infections, the increasing focus on improved patient care, and active government efforts to control the spread of HAIs. The prevalence of HAIs is climbing due to several factors, including higher hospital admissions, extended patient stays, and the growing use of invasive medical devices. Common infections such as urinary tract infections, pneumonia, and bloodstream infections are contributing to the demand for effective therapeutic solutions. Additionally, the growing population of immunocompromised patients further increases the susceptibility to these infections.

By drug type, the market is segmented into antibacterial, antiviral, antifungal, and other drugs. In 2023, antibacterial drugs dominated the market with a revenue of USD 9.2 billion. These drugs are essential for treating HAIs, especially with the increasing presence of antibiotic-resistant bacteria in healthcare environments. Antibacterial drugs are critical in addressing infections caused by resistant strains like MRSA and Clostridium difficile, which require potent therapeutic interventions.

In terms of administration routes, the market is divided into intravenous (IV), oral, topical, and inhalation therapies. The IV segment led the market, generating USD 5.7 billion in 2023. IV administration is the preferred method in hospital settings, as it ensures the rapid delivery of medications directly into the bloodstream. This is particularly important for managing severe infections, where quick therapeutic action is needed to combat life-threatening conditions. The high efficacy and immediate impact of IV-administered drugs make it the go-to option for managing critical HAI cases.

The North American market accounted for USD 4.7 billion in 2023 and is expected to grow at a CAGR of 2.5% between 2024 and 2032. The demand for HAI therapeutics in the region is driven by the high rate of infections and the presence of an advanced healthcare system. North America's vast network of hospitals and healthcare facilities increases the risk of HAIs, making infection control measures essential. The presence of leading pharmaceutical companies and ongoing research and development efforts also contribute to the development and availability of advanced treatment options, further fueling market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of hospital-acquired infections
    • 3.2.1.2 Advancements in medical technology and drug development
    • 3.2.1.3 Growing focus on patient safety and quality care
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of patient awareness and diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Pipeline analysis
• 3.10 Future market trends
• 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibacterial drugs
• 5.3 Antiviral drugs
• 5.4 Antifungal drugs
• 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intravenous (IV)
• 6.3 Oral
• 6.4 Topical
• 6.5 Inhalation

Chapter 7 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Surgical site infections
• 7.3 Bloodstream infections
• 7.4 Urinary tract infections
• 7.5 Ventilator-associated pneumonia
• 7.6 Other hospital infections

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 AbbVie
• 9.3 Allergan
• 9.4 Eugia Pharma
• 9.5 Bayer
• 9.6 DAIICHI SANKYO COMPANY
• 9.7 F. Hoffmann-La Roche
• 9.8 Glenmark Pharmaceuticals
• 9.9 GSK
• 9.10 Hikma Pharmaceuticals
• 9.11 Melinta Therapeutics
• 9.12 Merck & Co
• 9.13 Pfizer
• 9.14 Sanofi
• 9.15 Viatris